Open AccessEffect of spider venom on inhibition proliferation of TE13 cells in vivo and in vitro
Author(s) -
Gao Li,
Zhang Jing,
Liu Xinyan,
Zhao Min,
Li Lijun,
Liu Xin,
Zhao Baohua
Publication year - 2013
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12020
Subject(s) - venom , in vivo , medicine , in vitro , spider , pharmacology , biology , biochemistry , zoology , microbiology and biotechnology
Background The aim of this study was to evaluate the cytotoxic and antitumor activity of spider venom ( SV ). Methods Cell proliferation and cytotoxicity were determined by 3 H ‐methyl thymidine incorporation ([ 3 H ]‐ TDR ) assay. DNA fragmentation and cell cycle kinetics were analyzed by FACS . In vivo inhibition of tumor size of nude mice by SV (5.0, 10.0, 20.0 mg/kg mice) was constructed. Results SV exhibited significant anti‐cancer effects on human squamous esophageal carcinoma cells TE13 , mainly as a result of cell apoptosis induced by SV . The anti‐cancer effects were likely achieved through decreasing [ 3 H ]‐ TdR . TE13 cells treated with SV (25, 50, 100 μg/ mL ), which were arrested in the G 0 /G 1 phase. SV treatment leads to anti‐proliferation effects, and significant apoptosis in TE13 cells with reactive oxygen species ( ROS) levels can increase dramatically and decrease cellular mitochondrial membrane potential ( MMP ). In addition, Western blotting analysis showed that one of the pharmacological mechanisms of SV was to activate the expression of P21 . In vivo testing revealed that tumor size was significantly decreased after 21 days of treatment with the venom ( P < 0.01). Conclusions Our data showed that SVs could inhibit TE13 cell proliferation in vitro and in vivo .